The hematopoietic growth factors in acute leukemia: US perspective

Olga Frankfurt*, Martin S. Tallman

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations


The role of myeloid growth factors (GFs) in the management of acute leukemias has been evaluated extensively in multiple clinical trials. Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) have been given prior to, concurrently with, and/or sequentially after the chemotherapy with the goal of reducing the duration of neutropenia and consequently, the incidence and severity of infections, as well as improving the rate of remissions and overall survival (OS). GFs have also been studied as chemotherapy-sensitizing agents, in an effort to recruit dormant myeloid stem cells into the sensitive phase of the cycle. Additionally, GFs, shown to stimulate proliferation and differentiation of leukemia cells in vitro, have been evaluated as monotherapy in patients with acute leukemia.

Original languageEnglish (US)
Title of host publicationHematopoietic Growth Factors in Oncology
EditorsGary Lyman, David Dale
Number of pages31
StatePublished - 2011

Publication series

NameCancer Treatment and Research
ISSN (Print)0927-3042

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'The hematopoietic growth factors in acute leukemia: US perspective'. Together they form a unique fingerprint.

Cite this